이전|다음

단삼 및 활성 성분의 대장암 항암 분자기전 연구 진전

  • role： First author第一作者
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

  • Email：15957478520@163.com
  • Introduction：郭嘉宁，在读硕士，从事中医基础理论和中医药抗肿瘤研究，E-mail： 15957478520@163.com
GUO Jianing12,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

NI Xiaochen12,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

ZHANG Kaiyuan12,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

FAN Wei12,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

WANG Chuhang12,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Cancer Hospital， Hangzhou 310022，China

XU Chao13,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

    Traditional Chinese Medicine ''Preventing Disease'' Wisdom Health Project Research Center of Zhejiang， Hangzhou 310053，China

HUANG Jianbo124,  
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

    Traditional Chinese Medicine ''Preventing Disease'' Wisdom Health Project Research Center of Zhejiang， Hangzhou 310053，China

JIANG Tao124,  
  • role： Corresponding author通信作者
  • Affiliation：

    School of Basic Medical Sciences， Zhejiang Chinese Medical University， Hangzhou 310053，China

    Zhejiang Key Laboratory of Blood-Stasis-Toxin Syndrome， Hangzhou 310053，China

    Traditional Chinese Medicine ''Preventing Disease'' Wisdom Health Project Research Center of Zhejiang， Hangzhou 310053，China

  • Email：zgjtcm@zcmu.edu.cn
  • Introduction：张光霁，博士，主任医师，教授，从事中医基础理论和中医药抗肿瘤研究，E-mail： zgjtcm@zcmu.edu.cn
ZHANG Guangji124*

추상적인

대장암(CRC)은 가장 흔한 암 중 하나로, 다양한 암 중 발생률이 높으며 전 세계 암 환자의 두 번째 사망 원인입니다. CRC는 초기에는 특이적인 증상이 부족하며 대부분 환자가 중기 또는 말기에 진단되어 현재 소화기계 종양 분야에서 주요 연구 주제입니다. 현재 임상에서 CRC 수술 치료는 위험이 높고 전이, 재발, 약물 내성 및 방사선화학요법의 부작용 문제가 여전히 흔합니다. 중의학의 발전과 응용으로 인해 중약 및 그 활성 성분이 다중 표적, 다단계, 다중 효과를 통해 CRC 세포 증식, 침습, 이동 및 혈관 신생을 효과적으로 억제하고 CRC 세포의 세포자멸사 및 자가포식을 촉진하여 CRC 진행을 늦추는 것으로 밝혀졌으며, 이는 현재 CRC 치료 연구의 초점입니다. 단삼(Salvia miltiorrhiza)은 활혈거어, 통경지통, 청심제번, 냉혈소옹 등의 효능이 있으며, 디터페노이드, 페놀산, 플라보노이드, 다당류 및 질소 함유물, 스테로이드, 락톤 등 다양한 화학 성분을 함유하고 있습니다. 본 논문은 단삼 및 그 활성 성분의 항CRC 분자 기전에 대해 종합적으로 고찰하였으며, 단삼 및 그 활성 성분이 CRC 세포 주기 차단, 세포자멸사 촉진, 세포 침습 및 이동 억제, 세포 자가포식 유도, 종양 혈관 신생 억제 및 종양 미세환경 재구성 등 여러 분자 기전을 통해 항CRC 효과를 발휘함을 밝혔다. 이는 단삼을 이용한 CRC 치료제 개발 및 임상 실천에 새로운 아이디어를 제공하는 것을 목표로 합니다.

키워드

단삼;활성 성분;대장암;분자기전;연구 진전

References

  1. 1.
    DEKKER E，TANIS P J，VLEUGELS J L A，et al. Colorectal cancer［J］.Lancet，2019，394（10207）：1467-1480.
  2. 2.
    LIN H，DAI W H，LIU C J，et al.Research progress on the anti-colorectal cancer effect of traditional Chinese medicine monomer［J］.Nat Prod Res Dev，2023，35（9）：1637-1649.
  3. 3.
    Chinese Society of Oncology Chinese Medical Association，Hospital Authority of National Health Commission of the People's Republic of China.Chinese guidelines for the diagnosis and treatment of colorectal cancer（2023 Edition）［J］.Med J Pumch，2023，14（4）：706-733.
  4. 4.
    TAN S P，GONG H W，LI C Y，et al.Research progress on blood-activating and stasis-dispelling traditional Chinese medicines and their formulas in the treatment of colorectal cancer［J］.Hubei J Tradit Chin Med，2023，45（11）：59-62.
  5. 5.
    REN M M，GU L M，YANG W J，et al.Experience of TCM master ZHOU Zhong-ying in the treatment of colorectal cancer from damp-heat stasis toxin and spleen Qi deficiency［J］.China J Tradit Chin Med Pharm，2022，37（8）：4488-4492.
  6. 6.
    CUI Z H，LIU J P，XU W C，et al.Treatment thoughts of TCM master LI Dian-gui oncolon polyp based on turbid toxin theory［J］.China J Tradit Chin Med Pharm，2023，38（2）：634-636.
  7. 7.
    LI X J，SONG C，WANG C，et al.Treatment of colorectal cancer by TCM Master PAN Minqiu［J］.J Hunan Univ Chin Med，2022，42（12）：1966-1972.
  8. 8.
    QIAN Y W.Professor FANG Zhijun's data mining and core prescriptionnetwork pharmacology research on drug use in thetreatment of colon cancer patients［D］.Nanjing：Nanjing University of Chinese Medicine，2024.
  9. 9.
    YANG Y T，WU D S，ZOU B，et al.Epidemiology of 1 030 cases of colorectal cancer and analysis of TCM symptom characteristics［J］.Clin J Tradit Chin Med，2024，36（8）：1542-1548.
  10. 10.
    SHAN X X，HONG B Z，LIU J，et al.Review of chemical composition，pharmacological effects，andclinical application of Salviae Miltiorrhizae Radix et Rhizoma andprediction of its Q-markers［J］.China J Chin Mater Med，2021，46（21）：5496-5511.
  11. 11.
    WAN X H，WANG Y L，ZHOU C Z，et al.Research progress on chemical constituents and pharmacological effeets of Salvia miltiorrhiza［J］.Chin Tradit Herb Drugs，2020，51（3）：788-798.
  12. 12.
    LIAO J L，FAN Z X，MENG Q Y，et al.Research progress on antitumor molecular mechanism of active ingredient in Salvia miltiorrhiza［J］.Chin Tradit Herb Drugs，2024，55（18）：6402-6415.
  13. 13.
    HANAHAN D，WEINBERG R A.Hallmarks of cancer： The next generation［J］.Cell，2011，144（5）：646-674.
  14. 14.
    URREGO D，TOMCZAK A P，ZAHED F，et al.Potassium channels in cell cycle and cell proliferation［J］.Philos Trans R Soc Lond B Biol Sci，2014，369（1638）：94-103.
  15. 15.
    KIM M K，PARK G H，EO H J，et al.Tanshinone Ⅰ induces Cyclin D1 proteasomal degradation in an ERK1/2 dependent way in human colorectal cancer cells［J］.Fitoterapia，2015，101（1）：162-168.
  16. 16.
    BAHNASSY A A，ZEKRI A N，EL-HOUSSINI S，et al.Cyclin A and Cyclin D1 as significant prognostic markers in colorectal cancer patients［J］.BMC Gastroenterol，2004，4（1）：22-34.
  17. 17.
    FAN S J.Effect of tanshinone ⅡA on cell proliferation and apoptosis of rectal carcinoma SW480［D］.Hengyang：University of South China，2014.
  18. 18.
    XUE J L，JIN X Z，WAN X W，et al.Effects and mechanism of Tanshinone ⅡA in proliferation，apoptosis，and migration of human colon cancer cells［J］.Med Sci Monit，2019，25（1）：4793-4800.
  19. 19.
    GARTEL A L，TYNER A L.The role of the cyclin-dependent kinase inhibitor p21 in apoptosis［J］.Mol Cancer Ther，2002，1（8）：639-649.
  20. 20.
    SU C C，CHEN G W，KANG J C，et al.Growth inhibition and apoptosis induction by tanshinone ⅡA in human colon adenocarcinoma cells［J］.Planta Med，2008，74（11）：1357-1362.
  21. 21.
    WANG X Y，GAO A N，JIAO Y D，et al.Antitumor effect and molecular mechanism of antioxidant polysaccharides from Salvia miltiorrhiza Bunge in human colorectal carcinoma LoVo cells［J］.Int J Biol Macromol，2018，108（1）：625-634.
  22. 22.
    TAMBE Y，TERADO T，KIM C J，et al.Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer［J］.Mol Carcinog，2019，58（10）：1726-1737.
  23. 23.
    TERADO T，KIM C J，USHIO A，et al.Cryptotanshinone suppresses tumorigenesis by inhibiting lipogenesis and promoting reactive oxygen species production in KRAS-activated pancreatic cancer cells［J］.Int J Oncol，2022，61（3）：108-117.
  24. 24.
    LI K X，CAO W，SU Z，et al.Investigating the action mechanism of Danshen on colorectal cancer based on network pharmacology［J］.Clin J Chin Med，2022，14（13）：11-17.
  25. 25.
    LI H，WANG J H.Mechanism of Pl3K/Akt pathway in regulating colorectal cancer and traditional Chinese medicine treatment：A review［J］.Chin J Exp Tradit Med Form，2023，29（13）：254-263.
  26. 26.
    SHI M H，ZHANG X A，ZHANG S X，et al.Research progress of signaling pathways related to treatment of colorectal cancer with Chinese medicine：A review［J］.Chin J Exp Tradit Med Form，2022，28（8）：272-282.
  27. 27.
    CARNEIRO B A，EI-DEIRY W S.Targeting apoptosis in cancer therapy［J］.Nat Rev Clin Oncol，2020，17（7）：395-417.
  28. 28.
    VIKHANSKAYA F，LEE M K，MAZZOLETTI M，et al.Cancer-derived p53 mutants suppress p53-target gene expression：Potential mechanism for gain of function of mutant p53［J］.Nucleic Acids Res，2007，35（6）：2093-2104.
  29. 29.
    LU M J，WANG C，WANG J.Tanshinone I induces human colorectal cancer cell apoptosis：The potential roles of Aurora A-p53 and Survivin-mediated signaling pathways［J］.Int J Oncol，2016，49（2）：603-610.
  30. 30.
    TAMM I，WANG Y，SAUSVILLE E，et al.IAP-family protein Survivin inhibits caspase activity and apoptosis induced by Fas（CD95），Bax，Caspases，and anticancer drugs［J］.Cancer Res，1998，58（23）：5315-5320.
  31. 31.
    CAO YQ，TANG H B，WANG G H，et al.Targeting Survivin with tanshinone ⅡA inhibits tumor growth and overcomes chemoresistance in colorectal cancer［J］.Cell Death Discov，2023，9（1）：351-362.
  32. 32.
    FU X J，ZHAO W W，LI K K，et al.Cryptotanshinone inhibits the growth of HCT116 colorectal cancer cells through endoplasmic reticulum stress-mediated autophagy［J］.Front Pharmacol，2021，12（1）：653232.
  33. 33.
    WANG Y，ZHANG Z，AUYEUNG K K，et al.Cryptotanshinone-induced p53-dependent sensitization of colon cancer cells to apoptotic drive by regulation of calpain and calcium homeostasis［J］.Am J Chin Med，2020，48（5）：1179-1202.
  34. 34.
    WANG L，YEUNG J H K，HU T，et al.Dihydrotanshinone induces p53-independent but ROS-dependent apoptosis in colon cancer cells［J］.Life Sci，2013，93（8）：344-351.
  35. 35.
    WANG L，HU T，SHEN J，et al.Dihydrotanshinone Ⅰ induced apoptosis and autophagy through Caspase dependent pathway in colon cancer［J］.Phytomedicine，2015，22（12）：1079-1087.
  36. 36.
    WANG L，HU T，SHEN J，et al.Miltirone induced mitochondrial dysfunction and ROS-dependent apoptosis in colon cancer cells［J］.Life Sci，2016，151（1）：224-234.
  37. 37.
    BERGERS G，FENDT S M.The metabolism of cancer cells during metastasis［J］.Nat Rev Cancer，2021，21（3）：162-180.
  38. 38.
    ZHANG Z，YANG C，GAO W，et al.FoxA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer［J］.Cancer Lett，2015，361（2）：240-250.
  39. 39.
    LAMPROPOULOS P，ZIZI-SERMPETZOGLOU A，RIZOS S，et al.TGF-beta signalling in colon carcinogenesis［J］.Cancer Lett，2012，314（1）：1-7.
  40. 40.
    ZHANG R W，LIU Z G，XIE Y，et al.In vitro inhibition of invasion and metastasis in colon cancer cells by TanⅡA［J］.Genet Mol Res，2016，15（3）：gmr9008.
  41. 41.
    SHAN Y F，SHEN X，Xie Y K，et al.Inhibitory effects of tanshinone ⅡA on invasion and metastasis of human colon carcinoma cells［J］.Acta Pharmacol Sin，2009，30（11）：1537-1542.
  42. 42.
    ZHANG L，CHEN C，DUANMU J X，et al.Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system，PI3K/Akt/mTOR signaling and HIF-1α nuclear translocation［J］.Int Immunopharmacol，2018，65（1）：429-437.
  43. 43.
    CAO Y Z，LU K Q，XIA Y W，et al.Danshensu attenuated epithelial-mesenchymal transformation and chemoresistance of colon cancer cells induced by platelets［J］.Front Biosci（Landmark Ed），2022，27（5）：160-171.
  44. 44.
    JIANG Y L，XUN Y.Molecular mechanism of Salvia miltiorrhiza in the treatment of colorectal cancer based on network pharmacology and molecular docking technology［J］.Drug Des Devel Ther，2024，18（1）：425-441.
  45. 45.
    AMARAVADI R K，KIMMELMAN A C，DEBNATH JTargeting autophagy in cancer：Recent advances and future directions［J］.Cancer Discov，2019，9（9）：1167-1181.
  46. 46.
    KOCATURK N M，AKKOC Y，KIG C，et al.Autophagy as a molecular target for cancer treatment［J］.Eur J Pharm Sci，2019，134（1）：116-137.
  47. 47.
    QIAN J F，CAO Y，ZHANG J，et al.Tanshinone ⅡA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway［J］.Transl Cancer Res，2020，9（11）：6919-6928.
  48. 48.
    JIN S K，WHITE E.Role of autophagy in cancer：Management of metabolic stress［J］.Autophagy.2007，3（1）：28-31.
  49. 49.
    XU Z Y，JIANG H，ZHU Y H，et al.Cryptotanshinone induces ROS-dependent autophagy in multidrug-resistant colon cancer cells［J］.Chem Biol Interact，2017，273（1）：48-55.
  50. 50.
    POTOČNJAK I，ŠIMIĆ L，GOBIN I，et al.Antitumor activity of luteolin in human colon cancer SW620 cells is mediated by the ERK/FoxO3a signaling pathway［J］.Toxicol In Vitro，2020，66（1）：104852.
  51. 51.
    LI Y H，WU W Q，HE X J，et al.Expression of HF-1α，VEGF and correlation with tumor angiogenesis inthyroid tumors［J］.China Modern Doctor，2013，51（20）：73-75.
  52. 52.
    YE X F，GAO P，LI J P，et al.The study of the relationship between the expression of VEGF and MMP-2 and the tum or incursionm etastasis of non-small cell lung cancer［J］.Ningxia Med J，2009，31（12）：1098-1100.
  53. 53.
    ZOU W，QIAN C，ZHANG S，et al.Targeting the Ang2/Tie2 axis with tanshinone ⅡA elicits vascular normalization in ischemic injury and colon cancer［J］.Oxid Med Cell Longev，2021，11（1）：7037786.
  54. 54.
    SUI H，ZHAO J H，ZHOU L H，et al.Tanshinone ⅡA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer［J］.Cancer Lett，2017，403（1）：86-97.
  55. 55.
    SHATAT A S，MAHGOUP E M，RASHED M H，et al.Molecular mechanisms of extracellular-ATP-mediated colorectal cancer progression：Implication of purinergic receptors-mediated nucleocytoplasmic shuttling of HuR［J］.Purinergic Signal，2024，20（6）：669-680.
  56. 56.
    KRZYSTEK-KORPACKA M，DIAKOWSKA D，KAPTURKIEWICZ B，et al.Profiles of circulating inflammatory cytokines in colorectal cancer（CRC），high cancer risk conditions，and health are distinct.Possible implications for CRC screening and surveillance［J］.Cancer Lett，2013，337（1）：107-114.
  57. 57.
    CHEN J，PITMON E，WANG K P.Microbiome，inflammation and colorectal cancer［J］.Semin Immunol，2017，8（32）：43-53.
  58. 58.
    LIU L J，GAO H J，WEN T，et al.Tanshinone ⅡA attenuates AOM/DSS-induced colorectal tumorigenesis in mice via inhibition of intestinal inflammation［J］.Pharm Biol，2021，59（1）：89-96.
  59. 59.
    SONG M Y，QIAN C，ZHANG T，et al.Salvia miltiorrhiza Bunge aqueous extract attenuates infiltration of tumor-associated macrophages and potentiates anti-PD-L1 immunotherapy in colorectal cancer through modulating Cox2/PGE2 cascade［J］.J Ethnopharmacol，2023，316（1）：116735.
  60. 60.
    GUO M X，LIN Y X，CAI M Y，et al.Traditional Chinese medicine regulates tumor-associated macrophages incolorectal cancer：A review［J］.Chin J Exp Tradit Med Form，2024，30（22）：279-288.
  61. 61.
    WEI X M，GENG X C，LI L，et al.Construction of the syndrome differentiation and treatment system of the whole process olcolorectal cancer based on the pathogenesis theory of cancer-toxin［J］.China J Tradit Chin Med Pharm，2023，38（2）：572-575.
  62. 62.
    WU Y J，SUN X H，GUO H X，et al.Biological connotation of pathogenesis of colorectal cancer due todamp-heat accumulation based on immune response-intestinal microbial axis［J］.Chin J Exp Tradit Med Form，2024，30（6）：228-237.
  63. 63.
    LU H M，MA Y C，WANG M Y，et al.B7-H3 confers resistance to Vγ9Vδ2 T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis［J］.Cancer Immunol Immunother，2021，70（5）：1213-1226.
  64. 64.
    ZHOU B，LU Y W，ZHAO Z M，et al.B7-H4 expression is upregulated by PKCδ activation and contributes to PKCδ-induced cell motility in colorectal cancer［J］.Cancer Cell Int，2022，22（1）：147-163.

더 읽기

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website